Latest Insider Transactions at Nuo Therapeutics, Inc. (AURX)
This section provides a real-time view of insider transactions for Nuo Therapeutics, Inc. (AURX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nuo Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nuo Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Scott M. Pittman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
217,709
+1.34%
|
$0
$0.43 P/Share
|
|
Sep 18
2024
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
125,000
+1.08%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+2.54%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+2.5%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+0.88%
|
$0
$0.75 P/Share
|
|
Dec 19
2023
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.32%
|
$0
$0.5 P/Share
|
|
Dec 19
2023
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+10.63%
|
$0
$0.5 P/Share
|
|
Dec 19
2023
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+3.38%
|
$0
$0.5 P/Share
|
|
Aug 01
2023
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
62,500
+0.56%
|
$125,000
$2.0 P/Share
|
|
Aug 01
2023
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+2.2%
|
$200,000
$2.0 P/Share
|
|
Aug 01
2023
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+4.34%
|
$50,000
$2.0 P/Share
|
|
Nov 09
2022
|
David Emerson Jorden CEO/CFO |
SELL
Open market or private sale
|
Direct |
162,500
-0.87%
|
$162,500
$1.5 P/Share
|
|
Apr 29
2022
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
804,868
+6.82%
|
$804,868
$1.0 P/Share
|
|
Apr 29
2022
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+2.25%
|
$100,000
$1.0 P/Share
|
|
Apr 29
2022
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+4.54%
|
$25,000
$1.0 P/Share
|
|
Apr 29
2022
|
David Emerson Jorden CEO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,532
+0.49%
|
$10,532
$1.0 P/Share
|